Include All CSL Behring Country Sites

News Room

The most recent items of news in the Canadian Region are:

Health Canada Approves CSL Behring’s AFSTYLA for the Treatment of Hemophilia A
Health Canada has approved AFSTYLA [Antihemophilic Factor VIII (Recombinant), SingleChain], CSL Behring’s novel long-lasting recombinant factor VIII single-chain therapy for adults and children with hemophilia A. More.

CSL Canada is supporting “Missing Type” campaign.
Our web site does have missing letters, join the Canadian Blood Services “Missing Type” campaign. More.

CSL Behring Commemorates 2016 hae day :-) with Partnerships, Sponsorships and Hereditary Angioedema Awareness Events
CSL Behring joins the global HAE community today in recognition of the fifth annual hae day :-), an initiative led by HAEi, the international patient organization for C1-inhibitor deficiency, along with the support of its national member organizations, including the US Hereditary Angioedema Association (HAEA). More.